Literature DB >> 24013743

Alzheimer's and prion diseases: PDK1 at the crossroads.

Frédéric Checler1.   

Abstract

TACE-mediated proteolysis is a key event interfering with both Alzheimer's and prion diseases. A new study shows that phosphoinositide-dependent kinase-1 (PDK1) is activated by cellular prion protein, which alters membrane-associated TACE levels, thereby influencing both Alzheimer's and prion pathologies.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24013743     DOI： 10.1038/nm.3332

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  13 in total

Review 1.  Abeta-generating enzymes: recent advances in beta- and gamma-secretase research.

Authors:  R Vassar; M Citron
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

Review 2.  Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.

Authors:  Frédéric Checler; Bruno Vincent
Journal:  Trends Neurosci       Date:  2002-12       Impact factor: 13.837

Review 3.  The molecular pathology of Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Neuron       Date:  1991-04       Impact factor: 17.173

Review 4.  α-Secretase in Alzheimer's disease and beyond: mechanistic, regulation and function in the shedding of membrane proteins.

Authors:  Bruno Vincent; Frederic Checler
Journal:  Curr Alzheimer Res       Date:  2012-02       Impact factor: 3.498

5.  The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein.

Authors:  Moustapha Cissé; Eric Duplan; Marie-Victoire Guillot-Sestier; Joaquim Rumigny; Charlotte Bauer; Gilles Pagès; Hans-Dieter Orzechowski; Barbara E Slack; Frédéric Checler; Bruno Vincent
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

6.  α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)-associated cell death.

Authors:  Marie-Victoire Guillot-Sestier; Claire Sunyach; Sergio T Ferreira; Maria-Paz Marzolo; Charlotte Bauer; Aurélie Thevenet; Frédéric Checler
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

7.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.

Authors:  Moustapha Cissé; Brian Halabisky; Julie Harris; Nino Devidze; Dena B Dubal; Binggui Sun; Anna Orr; Gregor Lotz; Daniel H Kim; Patricia Hamto; Kaitlyn Ho; Gui-Qiu Yu; Lennart Mucke
Journal:  Nature       Date:  2010-11-28       Impact factor: 49.962

8.  A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation.

Authors:  Laura Westergard; Jessie A Turnbaugh; David A Harris
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

9.  Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.

Authors:  Ji Won Um; Haakon B Nygaard; Jacqueline K Heiss; Mikhail A Kostylev; Massimiliano Stagi; Alexander Vortmeyer; Thomas Wisniewski; Erik C Gunther; Stephen M Strittmatter
Journal:  Nat Neurosci       Date:  2012-07-22       Impact factor: 24.884

10.  An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo.

Authors:  Brian R Fluharty; Emiliano Biasini; Matteo Stravalaci; Alessandra Sclip; Luisa Diomede; Claudia Balducci; Pietro La Vitola; Massimo Messa; Laura Colombo; Gianluigi Forloni; Tiziana Borsello; Marco Gobbi; David A Harris
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157
View more
  1 in total

1.  Manipulating the Prion Protein Gene Sequence and Expression Levels with CRISPR/Cas9.

Authors:  Lech Kaczmarczyk; Ylva Mende; Branko Zevnik; Walker S Jackson
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.